Asset profile
AK104
Multispecific antibody
Phase 3underway
Evidence outlook · registrational
Non-Small Cell Lung Cancer: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2026-10-28.
NCT05215067: The study is a small, single-group, open-label trial of AK104 plus docetaxel without a placebo or active comparator, and its primary clinical endpoint is objective response rate. Because no results are posted, there is no reported primary-endpoint comparison to evaluate, making this weak evidence for AK104.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 58 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AK104: this drug | Phase 3 | Multispecific antibody | PD-1×CTLA-4 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK | ||
| Crizotinib | Approved | Small molecule | ALK, ROS1, MET/HGFR, and RON |
…and 45 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(58 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (17)
October 2026 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-10-28 · NCT06617416 · CT.gov ↗
What to watch
November 2026 (3)
Phase 3Gastric and Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2026-11 · NCT06341335 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2026-11-01 · NCT06508606 · CT.gov ↗
What to watch
Phase 2HCC, Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2026-11-30 · NCT06984718 · CT.gov ↗
What to watch
December 2026 (13)
Phase 1Melanoma (Skin Cancer)Recruiting
Est. primary completion 2026-12 · NCT07586904 · CT.gov ↗
What to watch
Phase 2MSI-H/dMMR Gastric Carcinoma and Colorectal CancerActive not recruiting
Est. primary completion 2026-12 · NCT04556253 · CT.gov ↗
What to watch
Phase 2/3Gastric Cancer, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2026-12 · NCT06221748 · CT.gov ↗
What to watch
Phase 2Soft Tissue SarcomaRecruiting
Est. primary completion 2026-12-01 · NCT05926700 · CT.gov ↗
What to watch
Phase 1/2Metastatic Pancreatic Ductal AdenocarcinomaActive not recruiting
Est. primary completion 2026-12-30 · NCT06646055 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-30 · NCT06467500 · CT.gov ↗
What to watch
Early phase / not applicableMetastatic Colorectal CancerRecruiting
Est. primary completion 2026-12-30 · NCT06551207 · CT.gov ↗
What to watch
Phase 1/2SCLC, Extensive StageActive not recruiting
Est. primary completion 2026-12-31 · NCT06477523 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT05944224 · CT.gov ↗
What to watch
Phase 2Combined Hepatocellular-cholangiocarcinoma, Liver NeoplasmsNot yet recruiting
Est. primary completion 2026-12-31 · NCT07243951 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT06769971 · CT.gov ↗
What to watch
Phase 2Female, Age ≥ 18 Years Old, No Previous Systemic Treatment for the Current Disease, Including Surgery …Recruiting
Est. primary completion 2026-12-31 · NCT07104149 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT05747716 · CT.gov ↗
What to watch
2027 (24)
January 2027 (2)
March 2027 (1)
Phase 2Advanced Soft-tissue SarcomaRecruiting
Est. primary completion 2027-03-31 · NCT06367075 · CT.gov ↗
What to watch
April 2027 (3)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2027-04 · NCT05142423 · CT.gov ↗
What to watch
Phase 2Locally Advanced Rectal CancerNot yet recruiting
Est. primary completion 2027-04-24 · NCT05794750 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2027-04-30 · NCT06349967 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Colo-rectal Cancer, MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal CancersRecruiting
Est. primary completion 2027-05-01 · NCT07003022 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2027-05-10 · NCT07052253 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2Locally Advanced Esophageal Squamous Cell Carcinoma, Neoadjuvant TherapyRecruiting
Est. primary completion 2027-06-01 · NCT06356688 · CT.gov ↗
What to watch
Phase 2Pleural MesotheliomaNot yet recruiting
Est. primary completion 2027-06-20 · NCT06416930 · CT.gov ↗
What to watch
Phase 2Previously Treated, Advanced, Biliary Tract CancersActive not recruiting
Est. primary completion 2027-06-30 · NCT07635290 · CT.gov ↗
What to watch
August 2027 (3)
Phase 2Carcinomas, Cervix Cancer, Cervical CancerActive not recruiting
Est. primary completion 2027-08-01 · NCT05063916 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal Carcinoma, Nasopharyngeal CancerActive not recruiting
Est. primary completion 2027-08-01 · NCT05587374 · CT.gov ↗
What to watch
Phase 1/2Kidney Cancer, RCC, Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2027-08-31 · NCT06577961 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy, Efficacy, SafetyNot yet recruiting
Est. primary completion 2027-10-31 · NCT06542549 · CT.gov ↗
What to watch
November 2027 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-01 · NCT06702826 · CT.gov ↗
What to watch
Phase 3Gastric / Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-11-17 · NCT07449780 · CT.gov ↗
What to watch
Phase 1/2Advanced Gastric Cancer, Advanced Colorectal Cancer, Advanced Ovarian Cancer, Peritoneal MetastasisActive not recruiting
Est. primary completion 2027-11-30 · NCT06940921 · CT.gov ↗
What to watch
December 2027 (6)
Phase 2Extensive-stage Small Cell Lung Cancer (ES-SCLC)Recruiting
Est. primary completion 2027-12 · NCT07245446 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, ChemotherapyRecruiting
Est. primary completion 2027-12 · NCT05941741 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer Liver Metastases (CRLM)Recruiting
Est. primary completion 2027-12-01 · NCT07544784 · CT.gov ↗
What to watch
Phase 1Melanoma, Mucosal Melanoma, Metastatic MelanomaEnrolling by invitation
Est. primary completion 2027-12-31 · NCT06424626 · CT.gov ↗
What to watch
Phase 2Cervical Cancer Stage IVRecruiting
Est. primary completion 2027-12-31 · NCT06998394 · CT.gov ↗
What to watch
Phase 2Esophageal CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT06681285 · CT.gov ↗
What to watch
2028 (8)
February 2028 (1)
Phase 1Pancreas Cancer, Pancreas Cancer, Duct Cell AdenocarcinomaNot yet recruiting
Est. primary completion 2028-02-23 · NCT06913218 · CT.gov ↗
What to watch
July 2028 (2)
August 2028 (1)
Phase 2Ovary CancerRecruiting
Est. primary completion 2028-08-01 · NCT06540729 · CT.gov ↗
What to watch
December 2028 (4)
Early phase / not applicableUterine Cervical NeoplasmNot yet recruiting
Est. primary completion 2028-12 · NCT06878196 · CT.gov ↗
What to watch
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07649174 · CT.gov ↗
What to watch
Phase 3Rectal CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT06832917 · CT.gov ↗
What to watch
Phase 3Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate, MPR …Recruiting
Est. primary completion 2028-12-31 · NCT06949033 · CT.gov ↗
What to watch
2029 (6)
February 2029 (1)
Phase 2Locally Advanced Cervical CancerNot yet recruiting
Est. primary completion 2029-02 · NCT07450963 · CT.gov ↗
What to watch
May 2029 (2)
Phase 2Gastric Cancer, Gastroesophageal-junction CancerRecruiting
Est. primary completion 2029-05-27 · NCT07631000 · CT.gov ↗
What to watch
Phase 2Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Biliary Tract CancerRecruiting
Est. primary completion 2029-05-31 · NCT06789848 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Gastric and Gastroesophageal Junction (GEJ) AdenocarcinomaRecruiting
Est. primary completion 2029-07 · NCT07023315 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3Gastric / Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2029-08-18 · NCT07700979 · CT.gov ↗
What to watch
September 2029 (1)
Phase 1Resectable Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-09-01 · NCT07446257 · CT.gov ↗
What to watch
2030 (2)
March 2030 (1)
Phase 2Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2030-03 · NCT07263919 · CT.gov ↗
What to watch
June 2030 (1)
Phase 3Resectable Colon Cancer, MSI-H/dMMR Colorectal CancerRecruiting
Est. primary completion 2030-06-15 · NCT07412613 · CT.gov ↗
What to watch
2031 (1)
May 2031 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-05-01 · NCT06946836 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.